Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune‐Mediated Inflammatory Diseases: A Systematic Review and Meta‐Analysis of Randomized Trials
Objective Janus kinase (JAK) inhibition effectively treats immune‐mediated inflammatory diseases (IMIDs); however, concern over the risk of major adverse cardiac events (MACE) and venous thromboembolism (VTE) remains. We aimed to evaluate the safety (VTE and MACE outcomes) of JAK inhibitors in the t...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-10-01
|
Series: | ACR Open Rheumatology |
Online Access: | https://doi.org/10.1002/acr2.11479 |